Shares of ValiRx (LON:VAL) opened at GBX 4.60 ($0.06) on Tuesday. ValiRx has a 1-year low of GBX 0.90 ($0.01) and a 1-year high of GBX 7.75 ($0.10). The company has a market cap of $10.43 and a price-to-earnings ratio of -76.67.
COPYRIGHT VIOLATION WARNING: “ValiRx (VAL) Earns Speculative Buy Rating from Beaufort Securities” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/23/valirx-val-earns-speculative-buy-rating-from-beaufort-securities.html.
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
What are top analysts saying about ValiRx? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ValiRx and related companies.